Compounds > bpr0l075
Page last updated: 2024-11-12

bpr0l075

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID10359957
CHEMBL ID364123
SCHEMBL ID565514
MeSH IDM0471476

Synonyms (18)

Synonym
bdbm50151101
(6-methoxy-1h-indol-3-yl)-(3,4,5-trimethoxy-phenyl)-methanone
(6-methoxy-1h-indol-3-yl)(3,4,5-trimethoxyphenyl)methanone
6-methoxy-3-(3'',4'',5''-trimethoxybenzoyl)-1h-indole
CHEMBL364123 ,
bpr0l075
methanone, (6-methoxy-1h-indol-3-yl)(3,4,5-trimethoxyphenyl)-
613679-11-1
6-methoxy-3-(3,4,5-trimethoxybenzoyl) indole
SCHEMBL565514
unii-w918223vq6
bpr-0l075
w918223vq6 ,
UZJVBXKFBQNDTQ-UHFFFAOYSA-N
DTXSID20210285
bpr-0l-075
SB19853
Q27292488

Research Excerpts

Overview

BPR0L075 is a potential anticancer drug candidate designed from Combretastatin A-4. It is a novel synthetic compound discovered through research to identify new microtubule inhibitors.

ExcerptReferenceRelevance
"BPR0L075 is a novel synthetic compound discovered through research to identify new microtubule inhibitors. "( BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo.
Chang, JY; Chang, YL; Chen, CP; Chen, CT; Chen, LT; Hsieh, HP; Kuo, CC; Lee, SJ; Liou, JP; Pan, WY, 2004)		3.21
"BPR0L075 (2) is a potential anticancer drug candidate designed from Combretastatin A-4 (1) based on the bioisosterism principle. "( Synthesis and evaluation of 3-aroylindoles as anticancer agents: metabolite approach.
Chang, CY; Chang, JY; Chen, CP; Chen, CT; Chen, YJ; Chiang, YK; Chu, CY; Coumar, MS; Hsiao, CL; Hsieh, HP; Kuo, CC; Kuo, FM; Lin, CY; Liou, JP; Sun, HY; Tan, UK; Wu, SY; Wu, YS; Yao, HT; Yeh, TK, 2009)		1.8

Bioavailability

ExcerptReferenceRelevance
" Among these, 7-azaindole core 12 showed potent in vitro anticancer activity and improved oral bioavailability (F = 35%) compared with 1 (F < 10%)."( Scaffold-hopping strategy: synthesis and biological evaluation of 5,6-fused bicyclic heteroaromatics to identify orally bioavailable anticancer agents.
Chang, CW; Chang, CY; Chang, JY; Coumar, MS; Hsieh, HP; Kuo, CC; Liao, CC; Lin, CY; Liou, JP; Shiao, HY; Shukla, P; Tung, YS; Wu, JS; Wu, SY; Wu, YS; Yeh, TK, 2011)		0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Tubulin beta-1 chainHomo sapiens (human)IC50 (µMol)2.18000.00051.987010.0000AID240662
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (8)

Processvia Protein(s)Taxonomy
platelet formationTubulin beta-1 chainHomo sapiens (human)
thyroid gland developmentTubulin beta-1 chainHomo sapiens (human)
microtubule polymerizationTubulin beta-1 chainHomo sapiens (human)
spindle assemblyTubulin beta-1 chainHomo sapiens (human)
thyroid hormone transportTubulin beta-1 chainHomo sapiens (human)
platelet aggregationTubulin beta-1 chainHomo sapiens (human)
mitotic cell cycleTubulin beta-1 chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin beta-1 chainHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
GTPase activityTubulin beta-1 chainHomo sapiens (human)
metal ion bindingTubulin beta-1 chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin beta-1 chainHomo sapiens (human)
GTP bindingTubulin beta-1 chainHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
cytoplasmTubulin beta-1 chainHomo sapiens (human)
microtubule cytoskeletonTubulin beta-1 chainHomo sapiens (human)
intercellular bridgeTubulin beta-1 chainHomo sapiens (human)
extracellular exosomeTubulin beta-1 chainHomo sapiens (human)
mitotic spindleTubulin beta-1 chainHomo sapiens (human)
microtubuleTubulin beta-1 chainHomo sapiens (human)
cytoplasmTubulin beta-1 chainHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (56)

Assay IDTitleYearJournalArticle
AID1294621Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTS assay2016Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9
Synthesis, biological evaluation and molecular docking studies of 2-amino-3,4,5-trimethoxyaroylindole derivatives as novel anticancer agents.
AID596600Half life in Sprague-Dawley rat plasma at 20 mg/kg, po2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Scaffold-hopping strategy: synthesis and biological evaluation of 5,6-fused bicyclic heteroaromatics to identify orally bioavailable anticancer agents.
AID240662Inhibition of tubulin polymerization2004Journal of medicinal chemistry, Aug-12, Volume: 47, Issue:17
Concise synthesis and structure-activity relationships of combretastatin A-4 analogues, 1-aroylindoles and 3-aroylindoles, as novel classes of potent antitubulin agents.
AID422584Metabolic stability in dog liver microsomes assessed as compound remaining per mg of protein at 1 uM after 30 mins2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Synthesis and evaluation of 3-aroylindoles as anticancer agents: metabolite approach.
AID596591Cytotoxicity against human MKN45 cells after 72 hrs by methylene blue dye assay2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Scaffold-hopping strategy: synthesis and biological evaluation of 5,6-fused bicyclic heteroaromatics to identify orally bioavailable anticancer agents.
AID280068Inhibition of proliferation of human H460 cells2007Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5
Potent antitubulin tumor cell cytotoxins based on 3-aroyl indazoles.
AID342519Cytotoxicity against mouse B16 cells assessed as cell viability after 48 hrs by MTT test2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Synthesis and biological evaluation of new disubstituted analogues of 6-methoxy-3-(3',4',5'-trimethoxybenzoyl)-1H-indole (BPR0L075), as potential antivascular agents.
AID422591Toxicity in nude mouse assessed as body weight gain at 10 mg/kg, iv administered 5 days per week for 3 consecutive weeks2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Synthesis and evaluation of 3-aroylindoles as anticancer agents: metabolite approach.
AID596599Half life in Sprague-Dawley rat plasma at 5 mg/kg, iv2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Scaffold-hopping strategy: synthesis and biological evaluation of 5,6-fused bicyclic heteroaromatics to identify orally bioavailable anticancer agents.
AID422577Cytotoxicity against human HT-29 cells after 72 hrs by methylene blue dye assay2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Synthesis and evaluation of 3-aroylindoles as anticancer agents: metabolite approach.
AID317991Antiproliferative activity against human CEM cells2008Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
Synthesis and biological evaluation of 1-methyl-2-(3',4',5'-trimethoxybenzoyl)-3-aminoindoles as a new class of antimitotic agents and tubulin inhibitors.
AID412963Growth inhibition of human HT-29 cells after 72 hrs by methylene blue dye assay2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Synthesis and structure-activity relationships of 2-amino-1-aroylnaphthalene and 2-hydroxy-1-aroylnaphthalenes as potent antitubulin agents.
AID317989Antiproliferative activity against mouse FM3A cells2008Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
Synthesis and biological evaluation of 1-methyl-2-(3',4',5'-trimethoxybenzoyl)-3-aminoindoles as a new class of antimitotic agents and tubulin inhibitors.
AID596597Clearance in Sprague-Dawley rat at 5 mg/kg, iv2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Scaffold-hopping strategy: synthesis and biological evaluation of 5,6-fused bicyclic heteroaromatics to identify orally bioavailable anticancer agents.
AID422579Displacement of [3H]colchicine from tubulin at 5 uM after 1 hr by scintillation counter2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Synthesis and evaluation of 3-aroylindoles as anticancer agents: metabolite approach.
AID317993Displacement of [3H]colchicine from bovine tubulin at 5 uM2008Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
Synthesis and biological evaluation of 1-methyl-2-(3',4',5'-trimethoxybenzoyl)-3-aminoindoles as a new class of antimitotic agents and tubulin inhibitors.
AID422581Inhibition of tubulin polymerization2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Synthesis and evaluation of 3-aroylindoles as anticancer agents: metabolite approach.
AID596592Metabolic stability in human liver microsomes assessed as compound remaining at 1 uM after 30 mins2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Scaffold-hopping strategy: synthesis and biological evaluation of 5,6-fused bicyclic heteroaromatics to identify orally bioavailable anticancer agents.
AID596603AUC in Sprague-Dawley rat at 20 mg/kg, po2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Scaffold-hopping strategy: synthesis and biological evaluation of 5,6-fused bicyclic heteroaromatics to identify orally bioavailable anticancer agents.
AID431441Antiproliferative activity against human H460 cells2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Indolobenzazepin-7-ones and 6-, 8-, and 9-membered ring derivatives as tubulin polymerization inhibitors: synthesis and structure--activity relationship studies.
AID248446Concentration required for the 50% inhibition of human stomach cancer (MKN45) cell line growth2004Journal of medicinal chemistry, Aug-12, Volume: 47, Issue:17
Concise synthesis and structure-activity relationships of combretastatin A-4 analogues, 1-aroylindoles and 3-aroylindoles, as novel classes of potent antitubulin agents.
AID422582Metabolic stability in mouse liver microsomes assessed as compound remaining per mg of protein at 1 uM after 30 mins2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Synthesis and evaluation of 3-aroylindoles as anticancer agents: metabolite approach.
AID342518Ratio of IC50 of drug to IC50 of colchicine for calf brain tubulin polymerization2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Synthesis and biological evaluation of new disubstituted analogues of 6-methoxy-3-(3',4',5'-trimethoxybenzoyl)-1H-indole (BPR0L075), as potential antivascular agents.
AID431419Inhibition of tubulin polymerization2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Indolobenzazepin-7-ones and 6-, 8-, and 9-membered ring derivatives as tubulin polymerization inhibitors: synthesis and structure--activity relationship studies.
AID317990Antiproliferative activity against human Molt4/C8 cells2008Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
Synthesis and biological evaluation of 1-methyl-2-(3',4',5'-trimethoxybenzoyl)-3-aminoindoles as a new class of antimitotic agents and tubulin inhibitors.
AID412969Displacement of [3H]colchicine from tubulin after 2 hrs at 5 uM2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Synthesis and structure-activity relationships of 2-amino-1-aroylnaphthalene and 2-hydroxy-1-aroylnaphthalenes as potent antitubulin agents.
AID317988Antiproliferative activity against mouse L1210 cells2008Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
Synthesis and biological evaluation of 1-methyl-2-(3',4',5'-trimethoxybenzoyl)-3-aminoindoles as a new class of antimitotic agents and tubulin inhibitors.
AID596598Volume of distribution at steady state in Sprague-Dawley rat at 5 mg/kg, iv2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Scaffold-hopping strategy: synthesis and biological evaluation of 5,6-fused bicyclic heteroaromatics to identify orally bioavailable anticancer agents.
AID317992Inhibition of bovine tubulin polymerization after 20 mins2008Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
Synthesis and biological evaluation of 1-methyl-2-(3',4',5'-trimethoxybenzoyl)-3-aminoindoles as a new class of antimitotic agents and tubulin inhibitors.
AID679133TP_TRANSPORTER: drug resistance in KB-VIN10 cells2004Cancer research, Jul-01, Volume: 64, Issue:13
BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo.
AID422588Antitumor activity in human KB cells xenografted nude mouse assessed as decrease in tumor size at 10 mg/kg, iv administered 5 days per week for 3 consecutive weeks2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Synthesis and evaluation of 3-aroylindoles as anticancer agents: metabolite approach.
AID422585Metabolic stability in human liver microsomes assessed as compound remaining per mg of protein at 1 uM after 30 mins2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Synthesis and evaluation of 3-aroylindoles as anticancer agents: metabolite approach.
AID596594Solubility of the compound in phosphate buffer at 2 mg at pH 7.4 after 24 hrs2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Scaffold-hopping strategy: synthesis and biological evaluation of 5,6-fused bicyclic heteroaromatics to identify orally bioavailable anticancer agents.
AID342520Induction of morphological changes in human EA.hy 926 cells assessed as rounding up after 2 hrs2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Synthesis and biological evaluation of new disubstituted analogues of 6-methoxy-3-(3',4',5'-trimethoxybenzoyl)-1H-indole (BPR0L075), as potential antivascular agents.
AID422583Metabolic stability in rat liver microsomes assessed as compound remaining per mg of protein at 1 uM after 30 mins2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Synthesis and evaluation of 3-aroylindoles as anticancer agents: metabolite approach.
AID1459949Antiproliferative activity against human A549 cells measured after 72 hrs by MTS assay2017European journal of medicinal chemistry, Jan-05, Volume: 1253-Aroylindoles display antitumor activity in vitro and in vivo: Effects of N1-substituents on biological activity.
AID412968Inhibition of tubulin polymerization after 30 mins2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Synthesis and structure-activity relationships of 2-amino-1-aroylnaphthalene and 2-hydroxy-1-aroylnaphthalenes as potent antitubulin agents.
AID412960Growth inhibition of human KB cells after 72 hrs by methylene blue dye assay2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Synthesis and structure-activity relationships of 2-amino-1-aroylnaphthalene and 2-hydroxy-1-aroylnaphthalenes as potent antitubulin agents.
AID431442Antiproliferative activity against human KB cells2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Indolobenzazepin-7-ones and 6-, 8-, and 9-membered ring derivatives as tubulin polymerization inhibitors: synthesis and structure--activity relationship studies.
AID596601Cmax in Sprague-Dawley rat at 20 mg/kg, po2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Scaffold-hopping strategy: synthesis and biological evaluation of 5,6-fused bicyclic heteroaromatics to identify orally bioavailable anticancer agents.
AID248447Concentration required for the 50% inhibition of human stomach cancer (NUGC3) cell line growth2004Journal of medicinal chemistry, Aug-12, Volume: 47, Issue:17
Concise synthesis and structure-activity relationships of combretastatin A-4 analogues, 1-aroylindoles and 3-aroylindoles, as novel classes of potent antitubulin agents.
AID248425Concentration required for the 50% inhibition of human breast cancer (MCF-7) cell line growth2004Journal of medicinal chemistry, Aug-12, Volume: 47, Issue:17
Concise synthesis and structure-activity relationships of combretastatin A-4 analogues, 1-aroylindoles and 3-aroylindoles, as novel classes of potent antitubulin agents.
AID412964Growth inhibition of human MKN45 cells after 72 hrs by methylene blue dye assay2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Synthesis and structure-activity relationships of 2-amino-1-aroylnaphthalene and 2-hydroxy-1-aroylnaphthalenes as potent antitubulin agents.
AID596590Cytotoxicity against human KB cells after 72 hrs by methylene blue dye assay2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Scaffold-hopping strategy: synthesis and biological evaluation of 5,6-fused bicyclic heteroaromatics to identify orally bioavailable anticancer agents.
AID412961Growth inhibition of human Pgp170 overexpressing multidrug resistant-KB-VIN10 cells after 72 hrs by methylene blue dye assay2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Synthesis and structure-activity relationships of 2-amino-1-aroylnaphthalene and 2-hydroxy-1-aroylnaphthalenes as potent antitubulin agents.
AID422576Cytotoxicity against human H460 cells after 72 hrs by methylene blue dye assay2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Synthesis and evaluation of 3-aroylindoles as anticancer agents: metabolite approach.
AID342521Inhibition of tubulin polymerization2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Synthesis and biological evaluation of new disubstituted analogues of 6-methoxy-3-(3',4',5'-trimethoxybenzoyl)-1H-indole (BPR0L075), as potential antivascular agents.
AID596602Tmax in Sprague-Dawley rat at 20 mg/kg, po2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Scaffold-hopping strategy: synthesis and biological evaluation of 5,6-fused bicyclic heteroaromatics to identify orally bioavailable anticancer agents.
AID596604Oral bioavailability in Sprague-Dawley rat at 20 mg/kg2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Scaffold-hopping strategy: synthesis and biological evaluation of 5,6-fused bicyclic heteroaromatics to identify orally bioavailable anticancer agents.
AID679134TP_TRANSPORTER: drug resistance in KB-TAX50 cells2004Cancer research, Jul-01, Volume: 64, Issue:13
BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo.
AID412962Growth inhibition of human H460 cells after 72 hrs by methylene blue dye assay2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Synthesis and structure-activity relationships of 2-amino-1-aroylnaphthalene and 2-hydroxy-1-aroylnaphthalenes as potent antitubulin agents.
AID422575Cytotoxicity against human KB cells after 72 hrs by methylene blue dye assay2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Synthesis and evaluation of 3-aroylindoles as anticancer agents: metabolite approach.
AID596593Aqueous solubility in distilled water at 2 mg after 24 hrs2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Scaffold-hopping strategy: synthesis and biological evaluation of 5,6-fused bicyclic heteroaromatics to identify orally bioavailable anticancer agents.
AID248448Concentration required for the 50% inhibition of human uterine cancer (MESSA) cell line growth2004Journal of medicinal chemistry, Aug-12, Volume: 47, Issue:17
Concise synthesis and structure-activity relationships of combretastatin A-4 analogues, 1-aroylindoles and 3-aroylindoles, as novel classes of potent antitubulin agents.
AID248331Concentration required for the 50% inhibition of human lung caner (A549) cell line growth2004Journal of medicinal chemistry, Aug-12, Volume: 47, Issue:17
Concise synthesis and structure-activity relationships of combretastatin A-4 analogues, 1-aroylindoles and 3-aroylindoles, as novel classes of potent antitubulin agents.
AID596596AUC in Sprague-Dawley rat at 5 mg/kg, iv2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Scaffold-hopping strategy: synthesis and biological evaluation of 5,6-fused bicyclic heteroaromatics to identify orally bioavailable anticancer agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's8 (72.73)29.6817
2010's3 (27.27)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
indibulin
indibulin: Tubulin Modulator/Antineoplastic Agent; structure in first source		2.0510
fluorouracil
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.		2.0510nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
vorinostat
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.. vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).		2.1510dicarboxylic acid diamide;
hydroxamic acid		antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor
vincristine
[no description available]		2.4320acetate ester;
formamides;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
tertiary alcohol;
tertiary amino compound;
vinca alkaloid		antineoplastic agent;
drug;
microtubule-destabilising agent;
plant metabolite;
tubulin modulator
colchicine
(S)-colchicine : A colchicine that has (S)-configuration. It is a secondary metabolite, has anti-inflammatory properties and is used to treat gout, crystal-induced joint inflammation, familial Mediterranean fever, and many other conditions.		3.1350alkaloid;
colchicine		anti-inflammatory agent;
gout suppressant;
mutagen
vinblastine
[no description available]		2.4420
daunorubicin
Daunorubicin: A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.. anthracycline : Anthracyclines are polyketides that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.. daunorubicin : A natural product found in Actinomadura roseola.		2.0310aminoglycoside antibiotic;
anthracycline;
p-quinones;
tetracenequinones		antineoplastic agent;
bacterial metabolite
paclitaxel
Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).		2.9540taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
etoposide
[no description available]		2.0410beta-D-glucoside;
furonaphthodioxole;
organic heterotetracyclic compound		antineoplastic agent;
DNA synthesis inhibitor
bortezomib
[no description available]		2.1510amino acid amide;
L-phenylalanine derivative;
pyrazines		antineoplastic agent;
antiprotozoal drug;
protease inhibitor;
proteasome inhibitor
trichostatin a
trichostatin A: chelates zinc ion in the active site of histone deacetylases, resulting in preventing histone unpacking so DNA is less available for transcription; do not confuse with TRICHOSANTHIN which is a protein; found in STREPTOMYCES		2.1510antibiotic antifungal agent;
hydroxamic acid;
trichostatin		bacterial metabolite;
EC 3.5.1.98 (histone deacetylase) inhibitor;
geroprotector
vinorelbine
[no description available]		2.0510acetate ester;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
ring assembly;
vinca alkaloid		antineoplastic agent;
photosensitizing agent
fosbretabulin
[no description available]		3.360stilbenoid
tubastatin a
[no description available]		2.1510hydroxamic acid;
pyridoindole;
tertiary amino compound		EC 3.5.1.98 (histone deacetylase) inhibitor
ConditionIndicatedRelationship StrengthStudiesTrials
Benign Neoplasms
[description not available]		02.4320
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		02.4320
Angiogenesis, Pathologic
[description not available]		02.0410
Cancer of Prostate
[description not available]		02.1510
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.		02.1510